Products for Research Use Only

Bazedoxifene-d4 (acetate)

CAT: 0804-HY-A0031S2Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-A0031S2Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Bazedoxifene-d4 (acetate) is the deuterium labeled Bazedoxifene[1]. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[2][3].
CAS Number
1795027-71-2
Product Name Alternative
TSE-424-d4 (acetate)
UNSPSC
12352005
Target
Estrogen Receptor/ERR
Type
Isotope-Labeled Compounds
Related Pathways
Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Solubility
10 mM in DMSO
Smiles
CC(O)=O.CC(C1=CC(O)=CC=C12)=C(C3=CC=C(C=C3)O)N2CC4=CC=C(C=C4)OC([2H])([2H])C([2H])([2H])N5CCCCCC5
Molecular Formula
C32H34D4N2O5
Molecular Weight
534.68
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Barry S Komm, et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology. 2005 Sep;146 (9) :3999-4008.|[3]Xiaojuan Wu, et al. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy. Mol Cancer Ther. 2016 Nov 15 (11) : 2609–2619.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported